Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Crit Rev Oncol Hematol. 2023 Oct;190:104115. doi: 10.1016/j.critrevonc.2023.104115. Epub 2023 Aug 24.
Immune checkpoint inhibitors(ICIs) have improved the survival of advanced esophageal squamous cell carcinoma (ESCC) patients. Radiotherapy is one of the common therapies to treat esophageal cancer. However, whether combination radiation therapy can increase the efficacy of immunotherapy is still up for debate. Radiotherapy combined with immunotherapy has proven to be a reliable and effective treatment for tumors, and it can work in combination with immunotherapy to achieve better anti-tumor effects. This review aims to discuss the efficacy and safety of combining radiotherapy and immunotherapy to treat ESCC by stages as well as the optimum radiotherapy dose and target volume, with a summary of clinical trials in ESCC.
免疫检查点抑制剂（ICIs）改善了晚期食管鳞状细胞癌（ESCC）患者的生存率。放射治疗是治疗食管癌的常用方法之一。然而，联合放射治疗是否能提高免疫治疗的疗效仍存在争议。放射治疗联合免疫治疗已被证明是治疗肿瘤的一种可靠有效的方法，它可以与免疫治疗联合使用，以达到更好的抗肿瘤效果。本综述旨在讨论按阶段联合放疗和免疫治疗 ESCC 的疗效和安全性，以及最佳放疗剂量和靶区体积，并对 ESCC 的临床试验进行总结。
